Home | Sitemap | Contact
Emcure Aids Info
Treatment Guidelines
- Adults & Adolescents
   (December 1st, 2009)
- Pediatrics
   (February 23, 2009)
- Perinatal Guidelines
   (April 29th, 2009)
- TB/HIV A Clinical Manual


Tibotec Pharmaceuticals has signed a royalty-free, non-exclusive license agreement with Emcure Pharmaceuticals Limited of India to distribute the Protease Inhibitor Darunavir (DRV) in India.

Tibotec has collaborated with Emcure because of the company’s strong reputation in India and extensive reach through its country-wide distribution network. The agreement will help to build a sustainable effort in India to ensure patients in need have access to Darunavir (DRV)

As a part of its Corporate Social Responsibility (CSR) initiatives Emcure supported a program at TAAL, Kalyan, on “Diet Habits for Positive People” with renowned clinician Dr. Ghanshyam Asrani.

Members of Network in Thane by People Living with HIV (NTP+) and Network of Raigad by People Living with HIV (NRP+) have attended the program and got benefited from it. The focus was to improve the diet habits of positive people to keep themselves healthy. The program has evoked tremendous response from the PLH. Apart from pamphlets, diet charts were distributed to the members.

 


Established in 1981, Emcure was born out of the vision to create a healthcare company that would address the vast healthcare needs. Our commitment and drive have propelled our growth from a single manufacturing facility during the genesis, to a range of world class manufacturing facilities spread across API, formulations & biotechnology


Emcure has pioneered the launch of numerous World's First ARV Combinations with special emphasis on Pediatric formulations to make therapy more convenient and compliant.



v  www.emcure.co.in
v  www.elaxim.co.in
v  www.chiralemcure.com

Home page | Contact us | Sitemap | Feedback
Site Designed & Maintained By HariSoft, Interactive Integrators